Navigation Links
InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
Date:9/17/2013

and strategic partnership activities in key international markets.  In terms of the U.S. market, we already began enrollment for our FDA-intended MASTER II trial.  And as we expand our current clinical activities for the Coronary market, we continue to bolster our product pipeline with advances for the Carotid and Peripheral Vasculature target indications," concluded Mr. Milinazzo.

Operational Overview  In fiscal year 2013, the Company announced superior results from the MASTER trial for its MGuard Embolic Protection Stent (EPS).The findings show the novel MGuard EPS provides a significant acute advantage in reducing ST segment elevation versus traditional bare metal and drug eluting stents. As a result, MGuard may hold the potential to prolong the survival of heart attack victims, as evidenced by the 30-day and 6-month data. 

The MASTER trial is an important study for InspireMD, as it is the first large, randomized clinical trial for the MGuard to date. As such, the results have gained much more credence among those in the medical community. The 12-month follow up results for the MASTER trial, scheduled to be released on October 29th, are expected to be an important data point for physicians evaluating the MGuard, as the first year is an important period for evaluating a patient that has received a stent during a heart attack. 

The results disclosed thus far from the MASTER trial have allowed the Company to begin the transition to a new commercial strategy in countries where the MGuard has received regulatory clearance.  This includes setting up the support structure for a direct sales team in certain European countries and advancing discussions with new strategic partners.  The Company recently entered into an agreement with Healthlink Europe, a medical device support services and distribution company, to provide logistical and customer support for InspireMD's commercial operations and clinical
'/>"/>

SOURCE InspireMD
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. InspireMD Announces First Quarter 2012 Financial Results
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
4. InspireMD to Present at Harvard Investors Group on June 27 in New York
5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
6. InspireMD Reports Results For Period Ending Sept. 30, 2012
7. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
8. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) today ... 30, 2013, compared to sales of $2,202,000 for the prior ... this quarter has also shown growth over the preceding quarter,s ... of this fiscal year. Markets that experienced sales increases over ...
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ... Consumables Market - Global Industry Analysis, Size, Share, Growth, ... their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... are used on patients in order to treat dental ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
Breaking Medicine Technology:Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2
... Niiki Pharma Inc. announced today that it has ... clinical trial of its lead product, NKP-1339. NKP-1339 is ... tumor survival and anti-apoptosis factor. The NKP-1339 ... in patients with advanced solid tumors resistant to multiple, ...
... 2012 ULURU Inc. (NYSE AMEX: ULU ... European license for Altrazeal® to include the Middle East and ... the territory, Helmut Kerschbaumer Chairman of Melmed Holdings AG, stated, ... marketing to the various sectors in these markets. We have ...
Cached Medicine Technology:Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339 2ULURU Inc. Extends the European Altrazeal® License to Include the Middle East and Africa 2
(Date:7/11/2014)... The Corn Farming industry experienced ... the heels of fresh biofuel demand. The Federal Renewable ... larger share of their farmland to cultivating high-value corn ... the mixing of 5.0% renewable content in gasoline across ... States created a key export market for Canadian corn, ...
(Date:7/11/2014)... CA (PRWEB) July 11, 2014 Ticket ... Bryan Tickets at the Sleep Train Amphitheatre in Wheatland, ... venues that can compare to what the Sleep Train Amphitheatre ... musical events and special attractions over the course of its ... 16th, the Sleep Train Amphitheatre in Wheatland (Sacramento metro area) ...
(Date:7/11/2014)... are insoluble colorants, which usually consist of inorganic compounds. ... and coloring. These are water and oil insoluble natural ... as paper, paints, plastics, and concrete. Binders are used ... to the substance. Some examples of pigments are titanium ... coloring action of pigments is due to the scattering ...
(Date:7/11/2014)... York, NY (PRWEB) July 11, 2014 ... dramatic increase in men seeking cosmetic surgery and hair ... year. With such an expansive range of medical tourism ... exceptional plastic surgery costs and achieve the ... to be renowned as the top name in the ...
(Date:7/11/2014)... prescribed exercise as medicine, according to a QUT ... is essential to reducing the risk of death ... QUT,s Institute of Health and Biomedical Innovation, said ... and mental health, health professionals should be prescribing ... Anderson and QUT,s Dr Charlotte Seib co-authored a ...
Breaking Medicine News(10 mins):Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 3Health News:Exercise is the best medicine: QUT study 2
... , CHARLOTTE, N.C., July 17 ... an affiliate of US HIFU -- a worldwide leader in ... focused ultrasound (HIFU) technologies -- officially launches Sonablate((R)) HIFU services ... Gandhi Cancer Institute & Research Centre (RGCI & RC) on ...
... Gene, brain activity may determine child,s temperament, study finds , ... easy baby or a fussy one may have nothing to ... certain gene and a particular pattern of brain activity may ... Canadian researchers examined the interaction between the DRD4 gene and ...
... remain volatile issues in the drive for bipartisan support , ... to overhaul the nation,s health-care system started to emerge from ... that this may, at long last, be the year that ... health care more affordable. , "I think we,re in a ...
... , DOYLESTOWN, Pa., July 17 The ... www.quigleyco.com , today announced that Ted Karkus, ... Executive Officer by the Board of Directors of the Company. The ... Chief Operating Officer. , , ...
... July 17 Masimo Corporation (Nasdaq: MASI ), ... pending litigation under which Masimo and Respironics will dismiss all claims and ... As part of the settlement, Respironics and Masimo have agreed upon ... , About Masimo , ...
... TSX: BMR , , TORONTO, July 17 /PRNewswire-FirstCall/ ... "Corporation") announced today that its Board of Directors has ... bid (the "Offer"), pursuant to which the Corporation will ... of its outstanding common shares ("Shares") at a price ...
Cached Medicine News:Health News:Innovative Prostate Cancer Treatment Known as Sonablate(R) HIFU Now Available at Third Site in India 2Health News:Easy Baby or Fussy -- It May Be Out of Mom's Control 2Health News:Congress Braces for Showdown Over Health-Care Reform 2Health News:Congress Braces for Showdown Over Health-Care Reform 3Health News:Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer 2Health News:Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer 3Health News:Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer 4Health News:Masimo Announces Settlement of Lawsuit 2Health News:Masimo Announces Settlement of Lawsuit 3Health News:Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid 2Health News:Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid 3Health News:Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid 4
... is an effective angina relief ... poor targets. Because it is ... the CO2 Heart Laser 2 ... timely operative decisions to revascularize ...
Ultrasensitive TSH EIA Thyroid Function 025-BC-1003...
TG (Ab) RIA Thyroid Function 014-HD 27.1 Thyroglobulin...
... The anti-TG test kit is a solid ... format. It is designed for the quantitative ... (TG) in serum or plasma. The microplate ... Calibrators, controls and patient samples are pipetted ...
Medicine Products: